Oxford COVID-19 vaccine: Early trials suggest “double protection” immunity

The prospective COVID-19 vaccine undergoing effectiveness trials at the University of Oxford has been shown to produce antibodies and ‘killer T-cells’, according to reports.

– News covered by Quincy Quarry News with commentary added.

Doubling down against the COVID-19 virus
A Getty Images illustration

Oxford COVID-19 vaccine: early trials suggest that it provides “double protection” immunity

Finally, some truly dramatic good news in the worldwide battle against the COVID-19 virus pandemic.

While Cambridge Massachusetts-based Moderna has understandably enjoyed positive regional medial coverage about its progress on developing a vaccine against the COVID-19 virus, researchers at the University of Oxford in the United Kingdom have announced that their prospective vaccine appears to give rise to COVID-19-specfic antibodies and “killer T-cells” in the blood of those in their test group.

Unclear for reasons obvious, however, is how long these apparent dual immunities last in those vaccinated.

Undergoing a vaccination
Image from Sunrise Senior Living

And for further good news, the huge pharmaceutical firm AstraZeneca announced that it has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine at no profit with deliveries starting by the end of 2020 should the vaccine be duly confirmed as effective.

Unclear, however, is if the prospective University of Oxford COVID-19 vaccine might be made available in the US or if it might be ignored in favor of a US-developed vaccine that may or may not provide the apparent double immunity provided by the prospective Oxford vaccine.

Source: Oxford vaccine: Early trials suggest “double protection” from coronavirus

QQ disclaimer